Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results

Dow Jones

Nov 10

By Nicholas G. Miller

Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations.

The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year.

In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated.

"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients," said Cogent Chief Executive Andrew Robbins.

The company said it planned to submit a new drug application for bezuclastinib in the first half of next year.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

November 10, 2025 09:08 ET (14:08 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582687216"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582687216\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582687216?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582687216","market":"us","top_or_hot":-1,"title":"Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n</p>\n<p>\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n</p>\n<p>\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n</p>\n<p>\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n</p>\n<p>\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:08 ET (14:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCogent Biosciences Shares Double On Tumor Drug Positive Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-10 22:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n</p>\n<p>\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n</p>\n<p>\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n</p>\n<p>\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n</p>\n<p>\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:08 ET (14:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582687216","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582687216","pubTimestamp":1762783680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations.The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year.In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated.\"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins.The company said it planned to submit a new drug application for bezuclastinib in the first half of next year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4532":"文艺复兴科技持仓","BK4089":"非传统电信运营商","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","CCOI":"Cogent Communications Group","COGT":"Cogent Biosciences, Inc.","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC"},"translate_title":"Cogent Biosciences股价因肿瘤药物试验结果呈阳性而翻倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COGT":0.9,"CCOI":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n\n\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n\n\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n\n\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n\n\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 09:08 ET (14:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}